Top Stories
The AstraZeneca R&D Center at Kendall Square will be home to nearly 2000 scientists working on the company's oncology, cell therapy, chronic disease and rare disease pipeline.
The round brings the biotech's total capital raised to $100 million.
The French biotech will use PacBio's HiFi and Kinnex long-read RNA sequencing to generate data from over 10,000 samples.
The biotech has a pair of degraders in Phase I testing for allergic diseases and Graves' disease, respectively.
The CROWN trial evaluated the drug versus daily oral antiretroviral therapy in people with a history of ART and unsuppressed HIV.
Conference News
Presentations will highlight data on cognition, function, neuropsychiatric symptoms, sleep, gastrointestinal tolerability, treatment patterns and psychotropic medication utilization in Alzheimer’s dis...
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, toda...
Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDTBOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Ody...
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the u...
COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcas...
